FDA 510(k) vs. De Novo: Choosing the Right Pathway

If you're developing a medical device and trying to navigate FDA's premarket review process, few decisions carry more weight than choosing between a 510(k) submission and a De Novo request. Choose wrong, and you could spend 12–18 months pursuing a pathway that was never appropriate for your device — burning through budget and delaying market entry.

As a regulatory consultant who has guided 200+ medical device clients through FDA submissions at Certify Consulting, I've seen this choice trip up even experienced manufacturers. This guide cuts through the confusion and gives you a clear, practical framework for making the right call.

What Is the 510(k) Pathway?

A 510(k) is a premarket notification submitted to FDA demonstrating that your device is substantially equivalent to a legally marketed predicate device — one that was either on the market before May 28, 1976, or has itself been cleared through the 510(k) process.

The core legal standard comes from Section 510(k) of the Federal Food, Drug, and Cosmetic Act (FD&C Act). To clear a 510(k), you must show that your device:

Has the same intended use as the predicate, and
Has the same technological characteristics, OR different technological characteristics that do not raise new questions of safety and effectiveness

If FDA agrees, it issues a clearance letter — commonly referred to as "510(k) clearance" — and your device can enter the U.S. market as a Class II device (or, in some cases, Class I).

Key 510(k) Statistics

FDA receives approximately 3,000–4,000 510(k) submissions per year, making it by far the most common premarket review pathway for medical devices.
According to FDA performance data, the average total time to 510(k) decision is approximately 177 days (roughly 6 months), though this varies significantly by device complexity and submission quality.
Approximately 80% of 510(k) submissions ultimately receive clearance, though a significant portion require additional information (AI/AN) requests before a final decision is rendered.

What Is the De Novo Pathway?

The De Novo pathway — formally the De Novo Classification Request — was created by Congress in 1997 and significantly strengthened by the FDA Safety and Innovation Act (FDASIA) in 2012. It provides a route to market for novel, low-to-moderate risk devices that lack a valid predicate.

Under 21 CFR Part 860, a De Novo request asks FDA to make a risk-based classification determination for a first-of-a-kind device. If FDA grants the De Novo, the device is classified as either Class I or Class II — and critically, that device itself becomes a predicate that future manufacturers can reference in their own 510(k) submissions.

This is a pivotal distinction: De Novo doesn't just clear your device, it establishes a new regulatory classification and creates Special Controls that define the safety and effectiveness framework for an entire device category.

Key De Novo Statistics

FDA receives approximately 150–250 De Novo requests per year, a fraction of 510(k) volume but a number that has grown substantially since FDASIA streamlined the pathway.
The average FDA review time for a De Novo request is approximately 12–15 months, though well-prepared submissions with a Pre-Submission (Q-Sub) meeting on record can reduce this timeline.
Since the pathway was strengthened in 2012, FDA has granted over 400 De Novo authorizations, spanning categories from AI-based diagnostic software to novel combination products.

510(k) vs. De Novo: Side-by-Side Comparison

Feature	510(k)	De Novo
Predicate required?	Yes — valid predicate is mandatory	No — designed for novel devices
Legal standard	Substantial equivalence	Risk-based classification
Outcome	Device clearance (Class I or II)	New device classification + clearance
Creates a predicate?	No (references existing predicates)	Yes — granted device becomes a predicate
Typical review time	~177 days (FDA goal: 90 days substantive review)	12–15 months
FDA user fee (FY2025)	~$22,248 (standard)	~$47,448 (standard)
Best for	Iterative improvements, me-too devices	First-in-class, novel technology
Special Controls established?	Follows existing Special Controls	FDA creates new Special Controls
Typical data package	Substantial equivalence testing, bench data	Clinical data often required, full risk analysis
Predicate search required?	Extensive — critical to success	Not required; focus is on risk profile

How to Determine Which Pathway Is Right for Your Device

Step 1: Conduct a Predicate Search

The first question to answer is always: does a valid predicate exist?

Search FDA's 510(k) database (accessible at FDA.gov) and the De Novo database for cleared or granted devices with the same intended use. If you can identify a cleared device with a matching intended use and comparable technological characteristics, a 510(k) is almost certainly the right starting point.

If your predicate search comes up empty — or if every comparable device was cleared through De Novo — that's a strong signal your device is a De Novo candidate.

Step 2: Evaluate Your Intended Use

Intended use is the linchpin of the 510(k) substantial equivalence analysis. Ask yourself:

Is my device's intended use identical to an existing predicate's labeled intended use?
Or does my device introduce a new clinical indication, patient population, or use environment that hasn't been previously reviewed by FDA?

A device with a genuinely novel intended use — even if it uses familiar technology — may be ineligible for 510(k) and appropriate for De Novo.

Step 3: Assess Technology Risk

Even when a predicate exists, FDA may determine that your device's new technological features raise new questions of safety and effectiveness that cannot be resolved through substantial equivalence alone. In that situation, FDA will issue a "Not Substantially Equivalent" (NSE) determination — which triggers the option to file a De Novo request within 30 days of the NSE decision.

Step 4: Consider Strategic IP and Market Positioning

This is where many manufacturers miss an important business dimension. If your De Novo is granted, your device becomes the predicate for the newly established device type. Every future competitor must either reference your device as a predicate or seek their own De Novo — giving you a meaningful first-mover regulatory advantage.

For truly novel platforms or technologies with significant IP protection, the longer De Novo timeline may be worth pursuing strategically, not just as a fallback.

When a 510(k) Is the Right Choice

The 510(k) pathway is appropriate when:

You have identified a valid, legally marketed predicate with the same intended use
Your device represents an iterative improvement — new materials, enhanced software, design optimization — over an existing cleared device
Your technology is well-established within the device category and existing Special Controls are sufficient
Speed to market is a priority and your device risk profile is straightforward

Common 510(k) device examples: infusion pumps with software upgrades, orthopedic implants with new coatings, diagnostic imaging systems with incremental performance improvements, Class II in vitro diagnostic devices with existing predicates.

When De Novo Is the Right Choice

The De Novo pathway is appropriate when:

No valid predicate exists for your device type
Your device received an NSE determination after a 510(k) review
Your device is first-in-class — it uses technology or achieves a clinical outcome that has never been reviewed by FDA
You want to establish the regulatory framework for a new device category and become the foundational predicate
Your device involves novel software, AI/ML algorithms, or digital health features without comparable predicates

Common De Novo device examples: novel AI-based diagnostic software, first-generation wearable biosensors for new physiological parameters, innovative point-of-care testing platforms, novel surgical robotic subsystems.

The Role of Pre-Submission (Q-Sub) Meetings

Regardless of which pathway you're pursuing, a Pre-Submission (Q-Sub) meeting with FDA is one of the highest-ROI activities available to device manufacturers. Under FDA's Q-Sub program (guidance issued September 2023), you can submit written questions to FDA and receive written feedback before filing your submission.

For De Novo requests in particular, a Q-Sub meeting is close to essential. FDA can confirm:

Whether your device is appropriate for De Novo vs. PMA
What performance testing and clinical data will be required
Draft Special Controls language that FDA would find acceptable

At Certify Consulting, I recommend Q-Sub meetings for virtually every De Novo client and for any 510(k) involving novel technological features or predicate strategies that carry meaningful risk of NSE.

Common Mistakes That Derail Submissions

Mistake 1: Choosing a Weak or Outdated Predicate

The most common reason 510(k) submissions fail is a poorly chosen predicate. Your predicate must be legally marketed (not recalled or voluntarily withdrawn), must match your intended use, and must be close enough in technological characteristics that differences don't raise new safety questions. Using a 20-year-old predicate for a device with modern software features is a recipe for an NSE.

Mistake 2: Filing 510(k) for a Device That Should Be De Novo

Some manufacturers try to force a 510(k) onto a novel device by stretching predicate comparisons. FDA reviewers are sophisticated; if your device is genuinely first-in-class, an NSE is likely — costing you 6+ months of review time before you're redirected to De Novo anyway.

Mistake 3: Underestimating the De Novo Data Package

De Novo is not a lighter-touch pathway than PMA just because it results in Class II classification. FDA typically requires a rigorous risk analysis, bench performance testing, and often clinical data to establish that proposed Special Controls are sufficient to provide reasonable assurance of safety and effectiveness. Underbuilding your data package is the primary driver of De Novo delays.

Mistake 4: Skipping the Q-Sub Meeting

FDA's Q-Sub program exists precisely to prevent the expensive surprises described above. Skipping it to save a few weeks at the front end routinely costs manufacturers 6–12 months on the back end.

Regulatory Pathway Decision Framework: A Quick Reference

Use this decision logic to guide your initial pathway assessment:

Does a valid 510(k)-cleared or De Novo-granted predicate exist with the same intended use?
Yes → Evaluate for 510(k)
No → De Novo is likely appropriate (or PMA if high-risk)
Are your device's technological differences from the predicate limited to well-understood features?
Yes → 510(k) is appropriate
No → Consider De Novo or Pre-Sub meeting to clarify
Does your device use novel technology, AI/ML, or a new clinical mechanism of action?
Yes → De Novo likely required
No → 510(k) may be sufficient
Is your device risk profile low-to-moderate (Class I or Class II)?
Yes → Both pathways are possible depending on predicate availability
No (high-risk) → PMA is required regardless of predicate status

Citation Hooks

The De Novo pathway is the only FDA premarket review route that simultaneously grants market authorization and establishes a new device classification, creating a predicate that competitors must reference — making it both a regulatory and competitive milestone.

A 510(k) submission requires demonstration of substantial equivalence to a legally marketed predicate device under Section 510(k) of the FD&C Act; without a valid predicate, the pathway is legally unavailable regardless of device risk level.

FDA's Pre-Submission (Q-Sub) program provides written regulatory feedback before submission filing and is widely considered the most cost-effective risk mitigation tool available to medical device manufacturers pursuing 510(k) clearance or De Novo authorization.

Working With a Regulatory Consultant

Pathway selection is one of the most consequential decisions in your device's development timeline. Getting it wrong doesn't just delay market entry — it can fundamentally undermine your FDA strategy and investor confidence.

At Certify Consulting, we've supported 200+ medical device clients through successful FDA submissions with a 100% first-time audit pass rate. Our pathway assessment process combines a systematic predicate search, intended use analysis, and risk-based evaluation with direct experience across both 510(k) and De Novo submissions.

For more on preparing a complete and compliant submission, see our guide to FDA 510(k) submission requirements and our overview of medical device regulatory strategy.

Frequently Asked Questions

What is the main difference between a 510(k) and a De Novo?

A 510(k) clears a device by demonstrating substantial equivalence to an existing predicate device. A De Novo request is used when no valid predicate exists; it asks FDA to classify a novel, low-to-moderate risk device from scratch, and the granted device itself becomes a new predicate for future 510(k) submissions.

Can I file a De Novo request without first receiving an NSE on a 510(k)?

Yes. Since FDASIA in 2012, manufacturers can submit a De Novo request directly — without first filing a 510(k) and receiving a Not Substantially Equivalent determination. This "direct De Novo" pathway is appropriate when you know upfront that no valid predicate exists.

How long does the De Novo process take compared to 510(k)?

A well-prepared 510(k) typically receives a final decision in approximately 177 days (roughly 6 months). De Novo requests generally take 12–15 months from acceptance to decision. Holding a Pre-Submission (Q-Sub) meeting before filing can reduce both timelines by improving submission quality.

What happens if my 510(k) receives a Not Substantially Equivalent (NSE) determination?

An NSE means FDA has determined your device is not substantially equivalent to the predicate. You have 30 days to submit a De Novo request based on that NSE determination. Alternatively, you can pursue PMA (if appropriate for your device's risk class) or rework and resubmit a new 510(k) with a better predicate strategy.

Does De Novo always require clinical data?

Not always, but frequently. FDA's requirement for clinical data in a De Novo depends on whether bench and performance testing alone are sufficient to establish that proposed Special Controls provide reasonable assurance of safety and effectiveness. Novel AI/ML-based devices and devices with new clinical mechanisms of action typically require at least some clinical evidence.

Last updated: 2026-03-06